Peter Buzy
2019
In 2019, Peter Buzy earned a total compensation of $4.2M as President, Gene Therapy at Catalent.
Compensation breakdown
| Non-Equity Incentive Plan | $134,548 |
|---|---|
| Option Awards | $2,000,009 |
| Salary | $49,253 |
| Stock Awards | $2,000,000 |
| Other | $2,239 |
| Total | $4,186,049 |
Buzy received $2M in option awards, accounting for 48% of the total pay in 2019.
Buzy also received $134.5K in non-equity incentive plan, $49.3K in salary, $2M in stock awards and $2.2K in other compensation.
Rankings
In 2019, Peter Buzy's compensation ranked 2,819th out of 13,971 executives tracked by ExecPay. In other words, Buzy earned more than 79.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,819 out of 13,971 | 80th |
Division Manufacturing | 1,021 out of 5,695 | 82nd |
Major group Chemicals And Allied Products | 338 out of 2,194 | 85th |
Industry group Drugs | 275 out of 1,880 | 85th |
Industry Pharmaceutical Preparations | 203 out of 1,392 | 85th |
Pay ratio
| Peter Buzy's Pay | $4,186,049 |
|---|---|
| Median Employee's Pay | $50,845 |
| Pay Ratio | 82to 1 |
In 2019, the annual total compensation of Peter Buzy was $4,186,049.
The annual total compensation of the median employee at Catalent was $50,845.
The ratio of Peter Buzy's pay to the pay of median employee was therefore 82 to one.
Source: SEC filing on September 20, 2019.
Buzy's colleagues
We found four more compensation records of executives who worked with Peter Buzy at Catalent in 2019.